Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059295
Filing Date
2025-04-28
Accepted
2025-04-28 16:07:40
Documents
19
Period of Report
2025-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A nuvl-20250425.htm   iXBRL DEF 14A 1516115
2 GRAPHIC img241477848_0.jpg GRAPHIC 173738
3 GRAPHIC img241477848_1.jpg GRAPHIC 90198
4 GRAPHIC img241477848_2.jpg GRAPHIC 173738
5 GRAPHIC img241477848_3.jpg GRAPHIC 483764
6 GRAPHIC img241477848_4.jpg GRAPHIC 453287
7 GRAPHIC img241477848_5.jpg GRAPHIC 206538
  Complete submission text file 0000950170-25-059295.txt   6092186

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20250425.xsd EX-101.SCH 20693
21 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20250425_htm.xml XML 235357
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40671 | Film No.: 25880334
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)